Global Patent Index - EP 4090339 A4

EP 4090339 A4 20240214 - CD122 WITH ALTERED ICD STAT SIGNALING

Title (en)

CD122 WITH ALTERED ICD STAT SIGNALING

Title (de)

CD122 MIT VERÄNDERTER ICD-STAT-SIGNALISIERUNG

Title (fr)

CD122 À SIGNALISATION ICD STAT MODIFIÉE

Publication

EP 4090339 A4 20240214 (EN)

Application

EP 21741938 A 20210114

Priority

  • US 202062961157 P 20200114
  • US 2021013519 W 20210114

Abstract (en)

[origin: WO2021146485A2] The present disclosure relates to modified human CD122, wherein the modified human CD122 comprises one or more STAT3 binding motifs. In some embodiments, the modified human CD122 is a modified orthogonal human CD122, which can be selectively activated by a cognate orthogonal IL2. The modified human CD122 is able to stimulate robust and sustained STAT3 and STAT5 signaling upon binding to a cognate IL2 ligand.

IPC 8 full level

A61K 35/17 (2015.01); A61K 38/17 (2006.01); A61K 48/00 (2006.01)

CPC (source: EP IL KR US)

A61K 38/177 (2013.01 - KR); A61K 38/2013 (2013.01 - KR); A61K 39/001119 (2018.08 - KR); A61K 39/4611 (2023.05 - EP IL KR US); A61K 39/4631 (2023.05 - EP IL KR US); A61K 39/464412 (2023.05 - EP IL KR US); A61K 39/464419 (2023.05 - EP IL KR US); A61P 31/00 (2018.01 - KR); A61P 37/00 (2018.01 - KR); C07K 5/1016 (2013.01 - KR); C07K 7/06 (2013.01 - KR); C07K 14/55 (2013.01 - EP IL KR US); C07K 14/7051 (2013.01 - KR US); C07K 14/7155 (2013.01 - EP IL KR US); C07K 16/2803 (2013.01 - KR); C07K 16/2878 (2013.01 - KR); C12N 5/0636 (2013.01 - EP IL KR US); C12N 15/63 (2013.01 - KR US); A61K 2039/5156 (2013.01 - KR); A61K 2039/5158 (2013.01 - KR); C07K 2317/622 (2013.01 - KR); C12N 2510/00 (2013.01 - KR)

Citation (search report)

  • [E] WO 2021119534 A2 20210617 - SYNTHEKINE INC [US]
  • [E] WO 2021207290 A1 20211014 - SYNTHEKINE INC [US]
  • [E] WO 2021146487 A2 20210722 - SYNTHEKINE INC [US]
  • [I] WO 2017044464 A1 20170316 - UNIV LELAND STANFORD JUNIOR [US], et al
  • [T] WO 2023172916 A2 20230914 - SYNTHEKINE INC [US]
  • [XP] KIM DONG ET AL: "Recent Advances in Allogeneic CAR-T Cells", BIOMOLECULES, vol. 10, no. 2, 10 February 2020 (2020-02-10), pages 263, XP055818528, DOI: 10.3390/biom10020263
  • [XP] TIAN YONGGUI ET AL: "Gene modification strategies for next-generation CAR T cells against solid cancers", JOURNAL OF HEMATOLOGY & ONCOLOGY, vol. 13, no. 1, 18 May 2020 (2020-05-18), XP055888282, Retrieved from the Internet <URL:https://link.springer.com/article/10.1186/s13045-020-00890-6/fulltext.html> DOI: 10.1186/s13045-020-00890-6

Designated contracting state (EPC)

AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DOCDB simple family (publication)

WO 2021146485 A2 20210722; WO 2021146485 A3 20210819; AU 2021208559 A1 20220707; CA 3165753 A1 20210722; CN 115038453 A 20220909; EP 4090339 A2 20221123; EP 4090339 A4 20240214; IL 293822 A 20220801; JP 2023510870 A 20230315; KR 20220131529 A 20220928; MX 2022008769 A 20221007; US 2023027899 A1 20230126

DOCDB simple family (application)

US 2021013519 W 20210114; AU 2021208559 A 20210114; CA 3165753 A 20210114; CN 202180009257 A 20210114; EP 21741938 A 20210114; IL 29382222 A 20220612; JP 2022542896 A 20210114; KR 20227027686 A 20210114; MX 2022008769 A 20210114; US 202117783505 A 20210114